Skip to main content
main-content

Oncology

Latest articles

24-06-2022 | Oncology | News | Article

Focal ultrasound may offer intermediate-risk prostate cancer alternative to radiation, surgery

Magnetic resonance imaging-guided focal ultrasound therapy is a feasible treatment for grade group 2–3 prostate cancer, indicate phase 2b trial findings published in The Lancet Oncology.

23-06-2022 | Oncology | News | Article

Tumor mutational burden ‘valuable biomarker’ for ICI response in NSCLC

High tumor mutational burden is associated with a better response to immune checkpoint inhibitors in people with non-small-cell lung cancer across all levels of PD-L1 expression, US researchers report.

23-06-2022 | Oncology | News | Article

Nordic childhood ALL review shows ‘fewer’ but ‘harder-to-cure’ relapses

The risk of relapse after treatment for childhood acute lymphoblastic leukaemia has decreased in the past 3 decades but the likelihood of successful treatment of relapse has not improved, suggests a review of three Nordic Society of Pediatric Hematology and Oncology clinical trials.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

22-06-2022 | Oncology | Highlight | Article

Enzalutamide during active surveillance may delay prostate cancer progression

The ENACT trial has demonstrated a significantly reduced risk for progression with the use of enzalutamide in men with low- or intermediate-risk localized prostate cancer undergoing active surveillance.

21-06-2022 | Oncology | News | Article

USPSTF continues to recommend against supplement use to prevent cancer, CVD in latest update

The USPSTF continues to recommend against the use of beta carotene and vitamin E for the primary prevention of cancer or cardiovascular disease in its updated 2022 recommendations, and maintains that the evidence is insufficient to assess the benefit–risk balance for the use of single- or paired-nutrient and multivitamin supplements.

20-06-2022 | Oncology | News | Article

Lorlatinib benefits extend to NSCLC patients with brain metastases

Patients with advanced ALK-positive non-small-cell lung cancer derive prolonged progression-free survival from first-line treatment with lorlatinib regardless of the presence of brain metastases, post-hoc analyses indicate.